



Universiteit  
Leiden  
The Netherlands

## **Differentiated thyroid carcinoma : treatment and clinical consequences of therapy**

Hoftijzer, H.C.

### **Citation**

Hoftijzer, H. C. (2011, May 12). *Differentiated thyroid carcinoma : treatment and clinical consequences of therapy*. Retrieved from <https://hdl.handle.net/1887/17641>

Version: Corrected Publisher's Version

License: [Licence agreement concerning inclusion of doctoral thesis in the Institutional Repository of the University of Leiden](#)

Downloaded from: <https://hdl.handle.net/1887/17641>

**Note:** To cite this publication please use the final published version (if applicable).

**The type 2 deiodinase Thr92Ala polymorphism is not associated with T4 dose in athyroid patients treated for differentiated thyroid carcinoma or patients with Hashimoto thyroiditis**

Hendrieke C. Hoftijzer, Karen A. Heemstra, Wendy M. van der Deure, Robin P. Peeters, Eric Fliers, Bente C. Appelhof, Wilmar M. Wiersinga, Eleonora P. Corssmit, Theo J. Visser, Johannes W. Smit,

*Clinical Endocrinology (Oxford)*, 2009 Aug; 71(2):279-283

## Abstract

### Objective

The type 2 deiodinase (D2)-Thr92Ala polymorphism has been associated with decreased D2 activity in some *in-vitro* experiments but not in others. So far no association between the D2-Thr92Ala polymorphism and serum thyroid hormone levels has been observed in humans, but in a recent study in athyroid patients, it was suggested that patients homozygous for the 92Ala allele needed higher T4 doses to achieve TSH suppression. We studied the association between the D2-Thr92Ala polymorphism with thyroid hormone levels and T4 dosage, in patients treated for differentiated thyroid carcinoma (DTC) and in a group of patients treated for Hashimoto thyroiditis.

### Patients

We studied 154 patients with DTC treated with TSH suppressive thyroid hormone replacement therapy for longer than 3 years and 141 patients with Hashimoto thyroiditis treated for at least 6 months with T4.

### Measurements

In all patients, serum levels of TSH, free T4, T3 and reverse T3 were measured and genotypes of the D2-Thr92Ala polymorphism were determined by Taqman assay. Univariate regression analysis was performed to determine the relation between T4 dosages and the D2-Thr92Ala polymorphism corrected for age, gender, BMI and serum TSH levels.

### Results

Both in DTC patients and Hashimoto patients, no association was observed between serum thyroid hormone levels or T4 dosages in presence of the D2-Thr92Ala polymorphism. Categorization of DTC patients according to degree of TSH suppression did not change these results.

### Conclusion

The D2-Thr92Ala polymorphism is not associated with thyroid hormone levels or T4 dose in patients treated for DTC or Hashimoto thyroiditis.

## Introduction

Most actions of thyroid hormone are mediated by the active form of thyroid hormone, T3. Serum and local T3 concentrations are mainly regulated by the iodothyronine deiodinases D1, D2 and D3 (1). D2 is essential for the local production of T3 through deiodination of T4. D2 is thus essential for the negative feedback regulation of thyroid hormone on TSH production in the pituitary. Several polymorphisms in D2 have been described (2–5). Controversy exists about the functional implications of the D2-Thr92Ala polymorphism, which has been associated with a decreased D2 activity in some *in-vitro* experiments (2) but not in others (5). So far no associations were found between the D2-Thr92Ala polymorphism and serum thyroid hormone levels in studies in healthy subjects (4,6,7). Torlontano *et al.* reported in thyroidectomized differentiated thyroid carcinoma (DTC) patients that homozygous carriers of the D2-Ala92 allele needed higher dosages of T4 (8). This difference was most prominently observed in the group with near-suppressed TSH (TSH values between 0.1 and 0.5 mU/l). Limitations of this study were that actual values of serum TSH levels for wild-type and homozygous groups within the near-suppressed TSH group were not given. It is therefore unclear whether TSH levels in both groups were indeed identical, which would be a key finding to ascribe the slight differences in T4 dose indeed to the polymorphism. The fact that serum T4 and T3 levels did not differ between the wild-type group and D2-Thr92Ala homozygotes is also remarkable. Moreover, as TSH is a continuous variable, we believe that the optimal analytic strategy would be by regression analysis, rather than a categorized approach. We therefore performed this study to reconfirm the findings of Torlontano *et al.* For this reason, we studied the association between the D2-Thr92Ala polymorphism and thyroid hormone levels and T4 dosage in 154 patients treated for DTC and 141 patients substituted with T4 for Hashimoto thyroiditis, using a linear regression model. In addition, we performed a categorized analysis to allow maximal comparability with the Torlontano study.

## Patients and methods

### Patients

Patients treated for DTC were recruited from the outpatient clinic of the Department of Endocrinology of the Leiden University Medical Center. All patients had been treated by near-total thyroidectomy followed by radioiodine ablation. After initial treatment, T4 therapy was started in a dose intended to suppress TSH levels below 0.4 mU/l for 15 years. All patients were cured as defined by the absence of 131-Iodine accumulation at diagnostic scintigraphy, serum thyroglobulin (Tg) concentrations

below 2 µg/l after TSH stimulation in the absence of Tg antibodies, a normal neck ultrasound and no other indication for disease. Patients with tumor relapse were only included if they had been subsequently cured. The Local Ethics Committee of the Leiden University Medical Center approved the study, and written informed consent was obtained from all subjects.

We also included 141 patients treated for at least 6 months with T4 therapy for Hashimoto thyroiditis. Serum TSH levels were between 0.11 and 4.0 mU/l. These patients were described earlier by Appelhof *et al.* (9).

### Study design

After an overnight fast, patients had a physical examination, including, height (meters [m]) and weight (kilograms [kg]). Blood was collected for determination of TSH, free T4 (FT4), T3 and reverse T3 (rT3). Serum samples were handled immediately and stored at -80 ° C in Sarstedt tubes. DNA was collected for genotyping of the D2-Thr92Ala polymorphism. To be able to compare our study with the study of Torlontano *et al.* (8) patients were categorized in groups with a suppressed TSH (< 0.1 mU/l), near-suppressed TSH (0.1–0.5 mU/l) or non-suppressed TSH (> 0.5 mU/l).

### Serum biochemistry

In the patients treated for DTC, serum FT4 and TSH were measured using a chemoluminescence immunoassay with a Modular Analytics E-170 system (intra-assay CV of 1.6–2.2% and 1.3–5.0%, respectively (Roche, Almere, the Netherlands). Serum T3 was measured with a fluorescence polarization immunoassay, CV 2.5–9.0%, on an ImX system (Abbott, Abbott Park, IL). Reverse T3 was measured using a RIA as described previously (10). In the patients treated for Hashimoto thyroiditis, serum TSH and FT4 were measured by time-resolved fluoroimmunoassay and serum T4 and T3 by in-house RIA methods (6).

### Genotyping

DNA was isolated from peripheral leucocytes by the salting out procedure (11). Genotypes of the D2-Thr92Ala polymorphism (rs225014) were determined using 5 ng genomic DNA in a 5' fluoregenic Taqman assay and reactions were performed in 384-wells format on ABI9700 2 × 384-well PCR machines with end-point reading on the ABI 7900HT TaqMan® machine (Applied Biosystems, Nieuwerkerk aan den IJssel, the Netherlands). Primer and probe sequences were optimized using the single nucleotide polymorphism assay-by design service of Applied Biosystems.

## Statistical analysis

Values are presented as mean  $\pm$  standard deviation (SD), median (range) or as numbers or proportions of patients. Deviation from Hardy–Weinberg Equilibrium was analyzed using a  $\chi^2$  -test. Dominant (Thr/Thr vs. Ala/X) and recessive (Thr/X vs. Ala/Ala) effects of the polymorphism were analyzed. The association between D2-Thr92Ala genotypes and T4 dosages or thyroid hormone levels was analyzed using multivariate regression analyses. This was corrected for age, gender, BMI and the natural logarithm of TSH levels. In addition, differences between the different D2 genotype groups were analyzed using unpaired *t* -test or ANCOVA. All calculations were performed using SPSS 12.0 for windows (SPSS, Inc., Chicago, IL). Differences were considered statistically significant at  $P < 0.05$ .

## Results

### Patient characteristics

We studied 154 DTC patients. Mean duration of TSH suppressive therapy was 9.2 years (range 0.5–42.6 years). Median duration of cure was 8.9 years (range 1.0–41.8 years). The mean dose of T4 was  $183 \pm 51$   $\mu\text{g}/\text{day}$ . Mean T4 dose was  $2.2 \pm 1.0$   $\mu\text{g}/\text{kg}$  body weight. We also studied 141 patients with Hashimoto thyroiditis on T4 replacement therapy. Genotyping of the D2-Thr92Ala polymorphism failed in two subjects. The remaining 139 patients were treated with T4 for a mean duration of  $7.3 \pm 5.8$  years. Mean T4 dose was  $125 \pm 46$   $\mu\text{g}/\text{day}$ .

### Thyroid hormone parameters and D2-Thr92Ala

Allele frequencies of the D2-Thr92Ala polymorphism in the DTC patients and Hashimoto thyroiditis patients were 39.6% and 40.3%, respectively. The genotype distributions did not deviate from Hardy–Weinberg equilibrium. Thyroid hormone levels and T4 dose for patients with DTC and Hashimoto thyroiditis are presented in **Table 1**. No differences were observed in thyroid hormone levels and T4 dose, corrected for BMI and TSH levels between wild-type, heterozygous and homozygous carriers of the D2-Thr92Ala polymorphism. Analyses were comparable when T4 dose was corrected for BMI. No differences were observed in the correlation between  $\ln\text{TSH}$  and T4 dose/kg or FT4 level for the different carriers of the D2-thr92ala polymorphism (**Figure 1a–d**).


**Table 1:** Deiodinase type 2 genotypes and thyroid hormone parameters

Genotype	Patients (n)	Age (yr)	Gender (m/f)	Weight (kg)	BMI (kg/m <sup>2</sup> )	TSH (mU/l)	FT4 (pmol/l)	T3 (nmol/l)	rT3 (nmol/l)	T4 dose (µg/day)	T4 dose (µg/kg)	Dose / kg x lnTSH
<b>DTC</b>												
WT Thr/Thr	60	47.2±12.4	13/47	76.1±15.3	25.6±4.7	0.05 (0.003-4.6)	22.72±3.89	1.49±0.28	0.60±0.23	186.3±58.2	2.09±1.04	-6.74±5.28
HeZ Ala/Thr	66	51.5±13.5	11/55	75.7±12.2	26.2±3.5	0.03 (0.003-4.9)	22.42±4.48	1.46±0.38	0.51±0.21	178.2±41.5	2.22±0.87	-6.81±4.96
HoZ Ala/Ala	28	48.3±10.2	5/23	74.7±14.8	25.8±5.9	0.05 (0.003-6.8)	21.66±4.27	1.40±0.33	0.56±0.19	185.9±58.4	2.19±1.07	-7.82±5.67
P-value		NS	NS	NS	NS	NS	NS	NS	NS	NS	NS	NS
<b>HT</b>												
WT Thr/Thr	47	46.6±8.6	5/42	78.5±17.8	27.8±5.4	2.02±1.76	14.46±2.87	1.73±0.36	ND	124.2±41.4	1.64±0.62	0.24±1.81
HeZ Ala/Thr	72	47.3±10.9	11/61	80.4±18.3	28.2±5.6	1.59±1.41	15.16±3.05	1.73±0.30	ND	127.6±50.6	1.64±0.71	-0.22±2.01
HoZ Ala/Ala	20	52.1±8.2	4/16	91.0±31.3	32.2±9.1	1.96±1.68	14.42±2.48	1.71±0.36	ND	116.3±38.1	1.36±0.51	0.17±1.45
P-value		NS	NS	0.046	0.026	NS	NS	NS	NS	NS	NS	NS

DTC= Differentiated thyroid carcinoma, HT= Hashimoto thyroiditis, WT= wild-type, HeZ= Heterozygous, HoZ= Homozygous, NS= Not significant, ND = no data available

Data are expressed as mean ± SD or number of patients, except for TSH which is median (range)

Analyses for TSH, FT4, T3 and T4 dose in HT patients are corrected for age, gender and BMI.



**Figure 1**

(A) Correlation between the natural logarithm of TSH and T4 dosage/kg for the different alleles of D2-Thr92Ala polymorphism in 154 patients with differentiated thyroid carcinoma. Lines: regression lines; bars: 95% confidence intervals of regression lines. (B) Correlation between the natural logarithm of TSH and FT4 for the different alleles of D2-Thr92Ala polymorphism in 154 patients with differentiated thyroid carcinoma. Lines: regression lines; bars: 95% confidence intervals of regression lines. (C) Correlation between the natural logarithm of TSH and T4 dosage/kg for the different alleles of D2-Thr92Ala polymorphism in 139 patients treated for Hashimoto thyroiditis. (D) Correlation between the natural logarithm of TSH and FT4 for the different alleles of D2-Thr92Ala polymorphism in 139 patients treated for Hashimoto thyroiditis.

## Discussion

We studied the association between the D2-Thr92Ala polymorphism and thyroid hormone levels and T4 dose in two separate groups of patients, treated for DTC or Hashimoto thyroiditis. Frequencies of the alleles of D2-Thr92Ala are in agreement with previous studies varying between 30.0% and 38.8% in patient with normal thyroid



function or not taking thyroid replacement or thyreostatic medication (3,4,6,7). The D2-Thr92Ala polymorphism was not associated with thyroid hormone parameters or T4 dosages in the two separate groups of patients included in our analyses. This is in accordance with previous studies (4–7). Torlontano *et al.* found that homozygous DTC carriers of the D2-Ala92 allele need higher T4 dosages (8). This association was observed in the near-suppressed TSH group, but not in the suppressed group. The study of Torlontano *et al.* has however, several limitations. TSH levels in the near-suppressed group of the different alleles were not given, which would have been useful to investigate whether the differences in T4 dose are not caused by alterations in TSH levels. In our study, no differences were observed in TSH levels or T4 dose for the different alleles with and without categorization according to the degree of TSH suppression in the DTC patients or Hashimoto patients. In addition, we believe that the analysis strategy should be primarily based on regression analysis rather than TSH categories, because for alterations in TSH levels should be corrected.

Remarkably, they did not find any differences in thyroid hormone levels suggesting that patients with D2-Ala92 alleles need a higher T4 dose to reach the same serum FT4 level. By inference, the Ala allele would not affect T4 feedback but rather T4 resorption. Torlontano *et al.* explain the discrepancies of their findings with previous studies by two arguments. First, they state that in previous studies thyroid hormone levels were within the wide reference range, which makes it difficult to detect subtle differences in thyroid hormone levels for different carriers of the D2-Thr92Ala polymorphism. However, they found this difference only in the near-suppressed group, which is an ill-defined group with a wide plasma TSH range including patients with normal TSH levels. Second, Torlontano *et al.* argue that the difference between their finding and earlier studies may be explained by the absence of a thyroid gland in their patients. However, in our analysis with athyroid DTC and Hashimoto patients, we could not confirm this. A *post hoc* power analysis for T4 dose and T4/kg showed a sufficient power of 100%. Therefore, it seems unlikely that underpowering of our study plays a major role in the negative findings.

In summary, we found no association between the D2-Thr92Ala polymorphism and thyroid hormone levels and T4 dose in two separate groups of patients treated for DTC or Hashimoto thyroiditis.

## References

1. Bianco AC, Kim BW. Deiodinases: implications of the local control of thyroid hormone action. *Journal of Clinical Investigation*. 2006 116 2571–2579.
2. Canani LH, Capp C, Dora JM, Meyer EL, Wagner MS, Harney JW, Larsen PR, Gross JL, Bianco AC, Maia AL. The type 2 deiodinase A/G (Thr92Ala) polymorphism is associated with decreased enzyme velocity and increased insulin resistance in patients with type 2 diabetes mellitus. *Journal of Clinical Endocrinology and Metabolism* 2005 90 3472–3478.
3. Mentuccia D, Proietti-Pannunzi L, Tanner K, Bacci V, Pollin TI, Poehlman ET, Shuldiner AR, Celi FS. Association between a novel variant of the human type 2 deiodinase gene Thr92Ala and insulin resistance: evidence of interaction with the Trp64Arg variant of the  $\beta$ -3-adrenergic receptor. *Diabetes* 2002 51 880–883.
4. Mentuccia D, Thomas MJ, Coppotelli G, Reinhart LJ, Mitchell BD, Shuldiner AR, Celi FS. The-Thr92Ala deiodinase type 2 (DIO2) variant is not associated with type 2 diabetes or indices of insulin resistance in the old order of Amish. *Thyroid* 2005 15 1223–1227.
5. Peeters RP, van den Beld AW, Attalki H, Toor H, de Rijke YB, Kuiper GG, Lamberts SW, Janssen JA, Uitterlinden AG, Visser TJ. A new polymorphism in the type II deiodinase gene is associated with circulating thyroid hormone parameters. *American Journal of Physiology-Endocrinology and Metabolism* 2005 289 E75–E81.
6. de Jong FJ, Peeters RP, den Heijer T, van der Deure WM, Hofman A, Uitterlinden AG, Visser TJ, Breteler MM. The association of polymorphisms in the type 1 and 2 deiodinase genes with circulating thyroid hormone parameters and atrophy of the medial temporal lobe. *Journal of Clinical Endocrinology and Metabolism* 2007 92 636–640.
7. Peeters RP, van Toor H, Klootwijk W, de Rijke YB, Kuiper GG, Uitterlinden AG, Visser TJ. Polymorphisms in thyroid hormone pathway genes are associated with plasma TSH and iodothyronine levels in healthy subjects. *Journal of Clinical Endocrinology and Metabolism* 2003 88 2880–2888.
8. Torlontano M, Durante C, Torrente I, Crocetti U, Augello G, Ronga G, Montesano T, Travascio L, Verrienti A, Bruno R, Santini S, D’Arcangelo P, Dallapiccola B, Filetti S, Trischitta V. Type 2 deiodinase polymorphism (threonine 92 alanine) predicts 1-thyroxine dose to achieve target thyrotropin levels in thyroidectomized patients. *Journal of Clinical Endocrinology and Metabolism* 2008 93 910–913.
9. Appelhof BC, Peeters RP, Wiersinga WM, Visser TJ, Wekking EM, Huysen J, Schene AH, Tijssen JG, Hoogendijk WJ, Fliers E. Polymorphisms in type 2 deiodinase are not associated with well-being, neurocognitive functioning, and preference for combined thyroxine/ 3,5,3’-triiodothyronine therapy. *Journal of Clinical Endocrinology and Metabolism* 2005 90 6296–299.
10. Visser TJ, Docter R, Hennemann G. Radioimmunoassay of reverse tri-iodothyronine. *Journal of Endocrinology* 1977 73 395–396.
11. Miller SA, Dykes DD, Polesky HF. A simple salting out procedure for extracting DNA from human nucleated cells. *Nucleic Acids Research* 1988 16 1215–1215.

